Department of Anesthesiology, Nordsjællands Hospital Hillerød
Hillerød, DK-3400, Denmark
NCT Number: NCT03372265
BACKGROUND
Total knee arthroplasty can be severely painful, and peripheral regional anesthesia is highly recommended as part of the perioperative pain treatment. Whether catheter-based techniques are better than single injection techniques are debatable. Furthermore, in catheter-based techniques, whether a low-dose automated, periodic infusion can produce similar analgesic effectiveness compared to a conventional, high dose, continuous infusion has never been explored.
AIM Comparison of the analgesic effectiveness of a low-dose automated, periodic infusion, a conventional continuous infusion and patient-controlled boluses only in catheter-based adductor canal blocks for patients undergoing total knee arthrplasty.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Phase 4
Hillerød, DK-3400, Denmark
BACKGROUND
Total knee arthroplasty (TKA) is a very common procedure, with more than 600.000 being performed annually in the US alone. This number is expected to increase to more than 3 million by 2030. The procedure is associated with intense, early postoperative pain, and half of the patients report moderate to severe pain the first 2-3 postoperative days (POD). Peripheral regional anesthesia (PRA) using single injection nerve blocks is highly recommended as part of a multimodal, perioperative, analgesic treatment.
Patients who are expected to have postoperative, severe pain exceeding the duration of a single injection nerve block may benefit from a catheter-based nerve block (CBNB) using either a continuous infusion (CI) or intermittent infusions of local anesthetics (LA). Intermittent boluses can be either patient-controlled or prescribed in combination with a continuous infusion or as prespecified intermittent boluses. Whether a CBNB treatment is superior to a single injection nerve block after orthopedic surgery remains unanswered. There are several challenges when using a CBNB treatment: The dosing or delivery method may be either insufficient and thus not pain relieving or too powerful resulting in dense motor block and limb anesthesia which may compromise safety and rehabilitation. The peripheral nerve block catheter may also displace and therefore deposit LA too far from the targeted nerve(s) to produce an effective nerve block.
Previous studies suggest that an automated periodic infusion (API) regimen is superior to CI. It seems that an API produces better pain control, a lower analgesic consumption over time and less motor inhibition. This is welldescribed for epidural catheters for laboring women, but evidence is also apparent in PRA. Adding a PCA bolus option to a catheter-based nerve block treatment may even out the difference in pain scores between API and CI.
However, it seems that API groups require less LA via PCA function. Reducing LA consumption is of great importance for ambulatory patients whose LA reservoir is limited, but also for all other orthopedic patients whose motor block should be minimized in order to optimize rehabilitation.
OBJECTIVES
To investigate whether a low-dose API with patient-controlled bolus option can produce a similar analgesic effect compared to a conventional, high dose, CI with patient-controlled bolus option in catheter-based peripheral nerve blocks for patients undergoing total knee arthrplasty.
Analgesic effectiveness will be compared with a group only given the patient controlled bolus option.
HYPOTHESIS
Low dose API with supplemental patient-controlled bolus option will provide pain-relieving therapy not inferior to a conventional CI with supplemental patient-controlled bolus option. The intervention group receiving patient-controlled boluses only will experience more pain breakthrough.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
Other names: Naropin 0.2%
Time frame: 1-72 hours
Postoperative pain using the visual analogue pain scale (VAS, 0-100 milimetres). Measurements will be patient-reported.
Time frame: 1-72 hours
Tablets consumed during the period of investigation
Time frame: 1-72 hours
Volume of ropivacaine 0.2 % (mL) used for patient-initiated boluses, 1-72 hours postoperatively
Time frame: 1-72 hours
Patient reported symptoms: dizziness, nausea, itching, constipation
Time frame: 1-72 hours
Pain (VAS, 0-100 milimetres) at the time of patient-initiated bolus
Time frame: 1-72 hours
Degree of motor nerve block, defined by paresis or paralysis in the knee flexion
Time frame: 1-72 hours
Insensitivity towards cold in the lateral aspects of the lower leg and beneath the foot. This will be recorded by the patient using a cold glass vial stored in a refrigator until its use
Nordsjaellands Hospital
Other
Catheter-based Peripheral Regional Anesthesia After Total Knee Arthroplasty: Comparison of Low Dose, Automated Periodic Infusions With Conventional High Dose, Continuous Infusion and Patient-initiated Infusions Only
Acronym: API-KNEE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07740252
Hysterectomy, Neurologic Manifestations
Tekirdağ, Turkey (Türkiye)
View Trial DetailsNCT07738861
Mandibular Molar Extraction, Neurologic Manifestations
Lahore, Pakistan
View Trial DetailsNCT06860100
Cardiovascular Diseases, Digestive System Diseases
Van, Tuşba, Turkey (Türkiye)
View Trial DetailsNCT07724678
Agnosia, Breast Cancer
Altındağ, Ankara, Turkey (Türkiye)
View Trial Details